Thalidomide does not interact with P-glycoprotein

Cancer Chemotherapy and Pharmacology

Volumn 57, Issue 5, 2006, Pages 599-606

  Zimmermann, Christian ^a   Gutmann, Heike ^b   Drewe, Juergen ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Enantiomers; Intestinal transport; P glycoprotein; Thalidomide

Indexed keywords

GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; RHODAMINE 123; RIFAMPICIN; THALIDOMIDE; VERAPAMIL;

ARTICLE; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; CHIRALITY; COCULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG TRANSPORT; ENANTIOMER; GENE OVEREXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INCUBATION TIME; LEUKEMIA CELL LINE; MONOLAYER CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEPARATION TECHNIQUE;

BIOLOGICAL TRANSPORT; CACO-2 CELLS; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; P-GLYCOPROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHODAMINE 123; RNA, MESSENGER; THALIDOMIDE;

EID: 32544440168     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-0087-3     Document Type: Article

References (38)

1. Sheskin J (1965) Further observation with thalidomide in lepra reactions. Lepr Rev 36:183-187
2. Meierhofer C, Wiedermann CJ (2003) New insights into the pharmacological and toxicological effects of thalidomide. Curr Opin Drug Discov Devel 6:92-99
3. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G (1993) Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177:1675-1680
4. Rowland TL, McHugh SM, Deighton J, Dearman RJ, Ewan PW, Kimber I (1998) Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells. Immunopharmacology 40:11-20
5. Kedar I, Mermershtain W, Ivgi H (2004) Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer patients who failed IL-2-based therapy. Int J Cancer 110:260-265
6. Meierhofer C, Dunzendorfer S, Wiedermann CJ (2001)Theoretical basis for the activity of thalidomide. BioDrugs 15:681-703
7. Singhal S, Mehta J (2002) Thalidomide in cancer. Biomed Pharmacother 56:4-12
8. Franks ME, Macpherson GR, Figg WD (2004) Thalidomide. Lancet 363:1802-1811
9. Eriksson T, Bjorkman S, Roth B, Fyge A, Hoglund P (1998) Enantiomers of thalidomide: blood distribution and the influence of serum albumin on chiral inversion and hydrolysis. Chirality 10:223-228
10. Eriksson T, Bjorkman S, Hoglund P (2001) Clinical pharmacology of thalidomide. Eur J Clin Pharmacol 57:365-376
11. Schumacher H, Smith RL, Williams RT (1965) The metabolism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species. Br J Pharmacol 25:338-351
12. Eriksson T, Bjorkman S, Roth B, Bjork H, Hoglund P (1998) Hydroxylated metabolites of thalidomide: formation in-vitro and in-vivo in man. J Pharm Pharmacol 50:1409-1416
13. Teo SK, Sabourin PJ, O'Brien K, Kook KA, Thomas SD (2000) Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients. J Biochem Mol Toxicol 14:140-147
14. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361-398
15. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 84:7735-7738
16. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR (1990) Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38:1277-1287
17. Takara K, Sakaeda T, Yagami T, Kobayashi H, Ohmoto N, Horinouchi M, Nishiguchi K, Okumura K (2002) Cytotoxic effects of 27 anticancer drugs in HeLa and MDR1-overexpressing derivative cell lines. Biol Pharm Bull 25:771-778
18. Lee CG, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, Ambudkar SV, Pastan I, Dey S (1998) HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 37:3594-3601
19. Borst P, Zelcer N, van Helvoort A (2000) ABC transporters in lipid transport. Biochim Biophys Acta 1486:128-144
20. Lin JH (2003) drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv Drug Deliv Rev 55:53-81
21. Fanelli M, Sarmiento R, Gattuso D, Carillio G, Capaccetti B, Vacca A, Roccaro AM, Gasparini G (2003) Thalidomide: a new anticancer drug?. Expert Opin Investig Drugs 12:1211-1225
22. Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152-162
23. Eriksson T, Bjorkman S (1997) Handling of blood samples for determination of thalidomide. Clin Chem 43:1094-1096
24. Fromm MF (2000) P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther 38:69-74
25. Westphal K, Weinbrenner A, Zschiesche M, Franke G, Knoke M, Oertel R, Fritz P, von Richter O, Warzok R, Hachenberg T, Kauffmann HM, Schrenk D, Terhaag B, Kroemer HK, Siegmund W (2000) Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin Pharmacol Ther 68:345-355
26. Lu Y, Yan Y, Wang XF (2004) Antiepileptic drug-induced multidrug resistance P-glycoprotein overexpression in astrocytes cultured from rat brains. Chin Med J (Engl) 117:1682-1686
27. Fardel O, Lecureur V, Guillouzo A (1993) Regulation by dexamethasone of P-glycoprotein expression in cultured rat hepatocytes. FEBS Lett 327:189-193
28. Zhou S, Chan E, Pan SQ, Huang M, Lee EJ (2004) Pharmacokinetic interactions of drugs with St John's wort. J Psychopharmacol 18:262-276
29. Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J (2003) Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial. Br J Clin Pharmacol 56:683-690
30. Pfrunder A, Gutmann H, Beglinger C, Drewe J (2003) Gene expression of CYP3A4, ABC-transporters (MDR1 and MRP1-MRP5) and hPXR in three different human colon carcinoma cell lines. J Pharm Pharmacol 55:59-66
31. Schuetz EG, Beck WT, Schuetz JD (1996) Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 49:311-318
32. Mordel A, Halkin H, Zulty L, Almog S, Ezra D (1993) Quinidine enhances digitalis toxicity at therapeutic serum digoxin levels. Clin Pharmacol Ther 53:457-462
33. Verschraagen M, Koks CH, Schellens JH, Beijnen JH (1999) P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil. Pharmacol Res 40:301-306
34. Khaliq Y, Gallicano K, Venance S, Kravcik S, Cameron DW (2000) Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus. Clin Pharmacol Ther 68:637-646
35. Artursson P, Palm K, Luthman K (2001) Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 46:27-43
36. Gutmann H, Fricker G, Torok M, Michael S, Beglinger C, Drewe J (1999) Evidence for different ABC-transporters in Caco-2 cells modulating drug uptake. Pharm Res 16:402-407
37. Hugger ED, Audus KL, Borchardt RT (2002) Effects of poly(ethylene glycol) on efflux transporter activity in Caco-2 cell monolayers. J Pharm Sci 91:1980-1990
38. Zhou S, Li Y, Kestell P, Paxton JW (2003) Determination of thalidomide in transport buffer for Caco-2 cell monolayers by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 785:165-173